

GEI-089

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: : PCT Date: 2/28/01
BRUNO DONATINI :
PCT No.: PCT/FR01/00577 :
Filed: Concurrently Herewith :
For: NOVEL...COMPOSITIONS :

600 Third Avenue
New York N.Y. 10016

PRELIMINARY AMENDMENT

Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend this application as follows:

IN THE CLAIMS:

Claim 5 (amended) Compositions according to claim 2, characterized in that the chitosan in acid form has a pH less than 6.

Claim 6 (amended) Compositions according to claim 2, characterized in that the chitosan in acid or cationic form is obtained by addition to the chitin of an organic acid chosen from among acetic acid, lactic acid, succinic acid, tartaric acid, ascorbic acid, citric acid, glutamic acid, methanesulphonic acid or ethanesulphonic acid.

Claim 7 (amended) Compositions according to claim 2 characterized in that the acid chitosan is obtained by addition of ascorbic acid or lactic acid to the chitin.

Claim 8 (amended) Compositions according to claim 3, characterized in that the basic chitosan has a pH of between 7 and 12.

Claim 9 (amended) Compositions according to claim 3, characterized in that the basic chitosan is an alkyl carboxamide of chitosan in which the alkyl group has from 2 to 6 carbon atoms.

Claim 11 (amended) Compositions according to claim 1, characterized in that the chitosan contents range from 30 to 70% by weight of the total mass.

Claim 12 (amended) Compositions according to claim 1, characterized in that the fungi or the parts of fungi such as the mycelium are used in fresh form or in the form of a dry extract.

Claim 13 (amended) Compositions according to claim 1, characterized in that the fungi are selected from among; *Armillaria Mellea*, *Agaricus bisorus*, *Boletus edulis*, *Cordyceps sinensis*, *Coriolus versicolor*, *Flammulina velutipes*, *Ganoderma lucidum*, *Hericim erinaceus*, *Hypsizygus marmoreus*, *Auricularia auricula-Judae*, *Phellinus linateus*, *Pleurotus ostreatus*, *Grifola frondosa*, *Agaricus campestris*, *Lentinus edodes*, *Tremela fuciformis*, and *Volvaria volvacea*.


Claim 14 (amended) Use of the compositions according to claim 1, with a view to the achievement of a dietary and/or pharmaceutical preparation suitable for combatting obesity, hypercholesterolemia, diabetes, cancer, memory disorders or asthma, in the form of galettes or biscuits and the like.

REMARKS

The present amendment is being submitted in order to conform the claims to the American practice.

Respectfully submitted,
Bierman, Muserlian and Lucas

By:


Charles A. Muserlian #19,683
Attorney for Applicant
Tel.# (212) 661-8000

CAM:ds
Enclosures

1. Fungi-based pharmaceutical and/or dietary compositions, characterised in that
that they contain one or more fungi or parts of edible fungi presenting therapeutic
5 properties and chitosan as chelating agent of contaminants such as heavy metals,
radioactive metals, weed-killers, fertilizers and insecticides, combined or mixed with
a diluting agent or a non-toxic vehicle.

10 2. Compositions according to claim 1, characterised in that the chitosan is an acid
chitosan.

3. Compositions according to claim 1, characterised in that that the chitosan is a
basic chitosan.

5 4. Compositions according to claim 1, characterised in that that the chitosan is
formed from a mixture of acid chitosan and basic chitosan.

10 5. Compositions according to one of claims 2 or ~~4~~, ^{characterized} characterised in that the chitosan
in acid form has a pH less than 6.

15 6. Compositions according to any one of claims 2, ~~4~~ and ~~5~~, ^{characterized} characterised in that the
chitosan in acid or cationic form is obtained by addition to the chitin of an organic
acid chosen from among acetic acid, lactic acid, succinic acid, tartaric acid, ascorbic
acid, citric acid, glutamic acid, methanesulphonic acid or ethanesulphonic acid.

25 7. Compositions according to any one of the claims 2, ~~4~~ and ~~5~~, ^{characterized} characterised in that
that the acid chitosan is obtained by addition of ascorbic acid or lactic acid to the
chitin.

30 8. Compositions according to ^{claim} one of ~~claims~~ 3 or ~~4~~, ^{characterized} characterised in that the basic
chitosan has a pH of between 7 and 12.

^{claim}
9. Compositions according to ~~one of claims 3, 4 or 8,~~ ^{characterized} characterised in that that the basic chitosan is an alkyl carboxamide of chitosan in which the alkyl group has from 2 to 6 carbon atoms.

5 ~~10. Compositions according to claim 9, characterised in that the basic chitosan is chitosan succinamide, chitosan acetamide or chitosan tartramide.~~

^{characterized}
11. Compositions according to any one of claims 1 to ~~10,~~ ^{characterized} characterised in that the chitosan contents range from 30 to 70 % by weight of the total mass.

10 ^{characterized}
12. Compositions according to any one of claims 1 to ~~11,~~ ^{characterized} characterised in that the fungi or the parts of fungi such as the mycelium are used in fresh form or in the form of a dry extract.

^{characterized}
5 13. Compositions according to any one of claims 1 to ~~12,~~ ^{characterized} characterised in that the fungi are selected from among: Armillaria Mellea, Agaricus bisporus, Boletus edulis, Cordyceps sinensis, Coriolus versicolor, Flammulina velutipes, Ganoderma lucidum, Hericium erinaceus, Hypsizygus marmoreus, Auricularia auricula-Judae, Phellinus linteus, Pleurotus ostreatus, Grifola frondosa, Agaricus campestris, Lentinus edodes, 10 Tremella fuciformis, and Volvaria volvacea.

25 14. Use of the compositions according to any one of claims 1 to ~~13,~~ with a view to the achievement of a dietary and/or pharmaceutical preparation suitable for combating obesity, hypercholesterolemia, diabetes, cancer, memory disorders or asthma, in the form of galettes or biscuits and the like.